‘Profile of cadherins: new marker useful for the diagnosis of Renal Cell Carcinoma (RCC)”. (Q3161196): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): Cancer is the leading cause of death in the world. The need to find new methods for early and more selective detection becomes increasingly evident. However, the heterogeneity of solid tumors makes this task difficult. Such heterogeneicity requires a “personalised treatment” that cannot be addressed with the current technology available for the diagnosis of many types of cancer, including Renal Cell Carcinoma (RCC). CRC is known as a type of...) |
(Created claim: summary (P836): Cancer is the leading cause of death in the world. The need to find new methods for early and more selective detection becomes increasingly evident. However, the heterogeneity of solid tumors makes this task difficult. Such heterogeneicity requires a “personalised treatment” that cannot be addressed with the current technology available for the diagnosis of many types of cancer, including Renal Cell Carcinoma (RCC). CRC is known as a type of si...) |
||||||||||||||
| Property / summary | |||||||||||||||
Cancer is the leading cause of death in the world. The need to find new methods for early and more selective detection becomes increasingly evident. However, the heterogeneity of solid tumors makes this task difficult. Such heterogeneicity requires a “personalised treatment” that cannot be addressed with the current technology available for the diagnosis of many types of cancer, including Renal Cell Carcinoma (RCC). CRC is known as a type of silent cancer because it is usually detected at an advanced stage, on the other hand, its incidence is increasing significantly in recent times. Currently, treatment for non-metastatic CRC is surgical resection, however, many patients end up developing metastases, which usually lead to death. This result is a consequence of the lack of early and reliable tumor markers for the diagnosis, monitoring and evaluation of the response to treatment, as well as innovative diagnostic techniques with highly selective. In the development of this project, the aim is to address these needs by: I) the discovery of new tumor markers based on cadherin expression profiles depending on the different subtypes of CRC (clear cells, chromophobic, oncocytoma, sarcomatoid, etc.), and (ii) the development of more sensitive diagnostic techniques based on magnetic nanoparticles (MNPS) functionalised with anti-cadherin antibodies. The success of this proposal brings implicit socio-economic benefits over the medium to long term as it would allow progress in early diagnosis and personalised treatment of RCC by improving survival rates, and the non-use of unnecessary treatments, resulting in a reduction in health costs. (English) | |||||||||||||||
| Property / summary: Cancer is the leading cause of death in the world. The need to find new methods for early and more selective detection becomes increasingly evident. However, the heterogeneity of solid tumors makes this task difficult. Such heterogeneicity requires a “personalised treatment” that cannot be addressed with the current technology available for the diagnosis of many types of cancer, including Renal Cell Carcinoma (RCC). CRC is known as a type of silent cancer because it is usually detected at an advanced stage, on the other hand, its incidence is increasing significantly in recent times. Currently, treatment for non-metastatic CRC is surgical resection, however, many patients end up developing metastases, which usually lead to death. This result is a consequence of the lack of early and reliable tumor markers for the diagnosis, monitoring and evaluation of the response to treatment, as well as innovative diagnostic techniques with highly selective. In the development of this project, the aim is to address these needs by: I) the discovery of new tumor markers based on cadherin expression profiles depending on the different subtypes of CRC (clear cells, chromophobic, oncocytoma, sarcomatoid, etc.), and (ii) the development of more sensitive diagnostic techniques based on magnetic nanoparticles (MNPS) functionalised with anti-cadherin antibodies. The success of this proposal brings implicit socio-economic benefits over the medium to long term as it would allow progress in early diagnosis and personalised treatment of RCC by improving survival rates, and the non-use of unnecessary treatments, resulting in a reduction in health costs. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Cancer is the leading cause of death in the world. The need to find new methods for early and more selective detection becomes increasingly evident. However, the heterogeneity of solid tumors makes this task difficult. Such heterogeneicity requires a “personalised treatment” that cannot be addressed with the current technology available for the diagnosis of many types of cancer, including Renal Cell Carcinoma (RCC). CRC is known as a type of silent cancer because it is usually detected at an advanced stage, on the other hand, its incidence is increasing significantly in recent times. Currently, treatment for non-metastatic CRC is surgical resection, however, many patients end up developing metastases, which usually lead to death. This result is a consequence of the lack of early and reliable tumor markers for the diagnosis, monitoring and evaluation of the response to treatment, as well as innovative diagnostic techniques with highly selective. In the development of this project, the aim is to address these needs by: I) the discovery of new tumor markers based on cadherin expression profiles depending on the different subtypes of CRC (clear cells, chromophobic, oncocytoma, sarcomatoid, etc.), and (ii) the development of more sensitive diagnostic techniques based on magnetic nanoparticles (MNPS) functionalised with anti-cadherin antibodies. The success of this proposal brings implicit socio-economic benefits over the medium to long term as it would allow progress in early diagnosis and personalised treatment of RCC by improving survival rates, and the non-use of unnecessary treatments, resulting in a reduction in health costs. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 17:20, 12 October 2021
Project Q3161196 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ‘Profile of cadherins: new marker useful for the diagnosis of Renal Cell Carcinoma (RCC)”. |
Project Q3161196 in Spain |
Statements
8,900.0 Euro
0 references
17,800.0 Euro
0 references
50.0 percent
0 references
1 January 2014
0 references
31 March 2017
0 references
INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD
0 references
41°39'7.67"N, 0°52'51.38"W
0 references
50297
0 references
El cáncer es la principal causa de muerte en el mundo. La necesidad de encontrar nuevos métodos para una detección más precoz y selectiva se hace cada día más evidente. Sin embargo, la heterogeneidad de los tumores sólidos dificulta esta tarea. Dicha heterogeneicidad requiere de un “tratamiento personalizado” que no es posible abordar con la tecnología actual disponible para el diagnóstico de muchos tipos de cáncer entre los que se incluye el Carcinoma de Células Renales(CCR). El CCR se conoce como un tipo de cáncer silencioso porque generalmente se detecta en una etapa avanzada, por otra parte, su incidencia está aumentando mucho en los últimos tiempos. En la actualidad, el tratamiento para el CCR no metastásico es la resección quirúrgica, sin embargo, muchos pacientes terminan desarrollando metástasis, que por lo general les conduce a la muerte. Este resultado es consecuencia de la falta de marcadores tumorales mas precoces y fiables, para el diagnóstico, seguimiento y evaluación de la respuesta al tratamiento, al igual que de innovadoras técnicas diagnósticas con altamente selectivas. En el desarrollo de este proyecto, se pretende abordar dichas necesidades mediante: i) el descubrimiento de nuevos marcadores tumorales basados en perfiles de expresión de cadherinas en función de los diferentes subtipos de CCR (células claras, cromófobo, oncocitoma, sarcomatoide, ..., etc), y ii) el desarrollo de técnicas de diagnóstico más sensibles basadas en nanopartículas magnéticas (MNPS) funcionalizadas con anticuerpos anti-cadherina. El éxito de esta propuesta, lleva implícitos beneficios socio-económicos a medio-largo plazo ya que permitiría un avance en el diagnóstico precoz y el tratamiento personalizado del CCR mediante la mejora de las tasas de supervivencia, y la no utilización de tratamientos innecesarios, lo que se traduce en una reducción de los costes sanitarios. (Spanish)
0 references
Cancer is the leading cause of death in the world. The need to find new methods for early and more selective detection becomes increasingly evident. However, the heterogeneity of solid tumors makes this task difficult. Such heterogeneicity requires a “personalised treatment” that cannot be addressed with the current technology available for the diagnosis of many types of cancer, including Renal Cell Carcinoma (RCC). CRC is known as a type of silent cancer because it is usually detected at an advanced stage, on the other hand, its incidence is increasing significantly in recent times. Currently, treatment for non-metastatic CRC is surgical resection, however, many patients end up developing metastases, which usually lead to death. This result is a consequence of the lack of early and reliable tumor markers for the diagnosis, monitoring and evaluation of the response to treatment, as well as innovative diagnostic techniques with highly selective. In the development of this project, the aim is to address these needs by: I) the discovery of new tumor markers based on cadherin expression profiles depending on the different subtypes of CRC (clear cells, chromophobic, oncocytoma, sarcomatoid, etc.), and (ii) the development of more sensitive diagnostic techniques based on magnetic nanoparticles (MNPS) functionalised with anti-cadherin antibodies. The success of this proposal brings implicit socio-economic benefits over the medium to long term as it would allow progress in early diagnosis and personalised treatment of RCC by improving survival rates, and the non-use of unnecessary treatments, resulting in a reduction in health costs. (English)
12 October 2021
0 references
Zaragoza
0 references
Identifiers
PI13_02140
0 references